Evgen Pharma PLC (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has today announced that Dr Stephen Franklin, the Company’s CEO, will present at a series of upcoming investor evenings.
The presentation will focus on the Phase II trials of SFX-01, the Company’s lead product, in the treatment of breast cancer and subarachnoid haemorrhage, a type of stroke.
Investors and shareholders wishing to register for the investor presentations may do so through the links provided below.
16 May 2018 – ShareSoc Growth Company Seminar, London
Time: The presentation will start at 5.30pm followed by a buffet and refreshments.
Location: Link Asset Services, 65 Gresham Street, London, EC2V 7NQ.
Link to register: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-london-16-may-2018/
17 May 2018 – Proactive Investors Healthcare, London
Time: The presentation will start at 6.00pm followed by drinks and canapés.
Location: Chesterfield Mayfair Hotel, 35 Charles Street, London, W1J 5EB.
Link to register: http://www.proactiveinvestors.co.uk/register/event_details/142
19 June 2018 – ShareSoc Growth Company Seminar, Manchester
Time: The presentation will start at 5.30pm followed by a buffet and refreshments.
Location: Kuits Solicitors, 7th Floor, Blackfriars House, Manchester, M3 2JA.
Link to register: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-19-june-2018/
A copy of the latest investor presentation will be available from 12pm on 15 May 2018 at: http://evgen.com/investors/shareholder-information/